Bonzun AB (publ) (BONZUN.ST)
SEK 0.01
(-2.78%)
SEK 0.01
(-2.78%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -28.58 Million SEK | -34.45% |
| 2022 | -14.15 Million SEK | -121.96% |
| 2021 | -6.37 Million SEK | -26.75% |
| 2020 | -8.95 Million SEK | 42.28% |
| 2019 | -12.04 Million SEK | -12.74% |
| 2018 | -7.73 Million SEK | 51.97% |
| 2017 | -16.09 Million SEK | -126.35% |
| 2016 | -7.11 Million SEK | -5.86% |
| 2015 | -6.71 Million SEK | -26.3% |
| 2014 | -5.32 Million SEK | 6.96% |
| 2013 | -6.1 Million SEK | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -5.66 Million TRY | -404.63% |
| 2024 Q1 | -1.12 Million SEK | -9.35% |
| 2023 Q4 | -1.02 Million SEK | 55.07% |
| 2023 Q1 | -805 Thousand SEK | 90.58% |
| 2023 Q2 | -1.88 Million SEK | -133.54% |
| 2023 FY | - SEK | -34.45% |
| 2023 Q3 | -2.28 Million SEK | -21.6% |
| 2022 Q4 | -8.54 Million SEK | -517.7% |
| 2022 Q2 | -2.1 Million SEK | -1331.29% |
| 2022 Q1 | -147 Thousand SEK | 93.51% |
| 2022 FY | - SEK | -121.96% |
| 2022 Q3 | -1.38 Million SEK | 34.22% |
| 2021 Q3 | -1.4 Million SEK | 0.0% |
| 2021 FY | - SEK | -26.75% |
| 2021 Q4 | -2.26 Million SEK | -61.59% |
| 2020 FY | - SEK | 42.28% |
| 2020 Q3 | -1.35 Million SEK | 0.0% |
| 2020 Q4 | -1.66 Million SEK | -23.09% |
| 2019 FY | - SEK | -12.74% |
| 2018 FY | - SEK | 51.97% |
| 2017 FY | - SEK | -126.35% |
| 2016 FY | - SEK | -5.86% |
| 2015 FY | - SEK | -26.3% |
| 2014 FY | - SEK | 6.96% |
| 2013 FY | - SEK | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Aino Health AB (publ) | -7.52 Million SEK | -279.662% |
| Kontigo Care AB (publ) | 1.67 Million SEK | 1803.501% |
| Medhelp Care Aktiebolag (publ) | 10 Million SEK | 385.79% |
| RaySearch Laboratories AB (publ) | 405.93 Million SEK | 107.042% |
| Surgical Science Sweden AB (publ) | 246.9 Million SEK | 111.577% |